Почетна › Кронова болест › Њујорк › New York City
Kliničke studije za Кронова болест u gradu New York City, NY
33 studija za Кронова болест traži učesnike na lokacijama u gradu New York City i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Тражи се учесникФаза 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Тражи се учесникФаза 3
- New York Gastroenterology Associates ( Site 0253), New York
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Тражи се учесникФаза 3
- NYU Langone Health - Inflammatory Bowel Disease Center (IBD) ( Site 5078), New York
- Weill Cornell Medical College, New-York Presbyterian Hospital ( Site 5079), New York
- New York Gastroenterology Associates ( Site 5013), New York
Iron Treatment for Iron Deficiency Anemia in Children and Young Adults With Crohn's Disease
Тражи се учесникФаза 4
- Weill Cornell Medicine, New York
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Тражи се учесникФаза 3
- New York Gastroenterology Associates, New York
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Тражи се учесникФаза 2/3
- Inflammatory Bowel Disease Center at NYU Langone, New York
- Weill Cornell Medical College, New York
- Lenox Hill Hospital, New York
- и још 1
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Тражи се учесникФаза 3
- New York Gastroenterology Associates, New York
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Тражи се учесникФаза 3
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Тражи се учесникФаза 3
- New York Gastroenterology Associates, New York
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Тражи се учесникФаза 2
- Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Тражи се учесникФаза 4
- New York Gastroenterology Associates, New York
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Тражи се учесникФаза 2
- New York Gastroenterology Associates - Upper East Side /ID# 281767, New York
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Тражи се учесникФаза 3
- NYU Langone Health-Site Number: 8400091, New York
- Weill Cornell Medicine - NewYork-Presbyterian Hospital-Site Number: 8400040, New York
- New York Gastroenterology Associates-Site Number: 8400009, New York
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Тражи се учесникФаза 3
- Manhattan Clinical Research, LLC-Site Number: 8400069, New York
- NYU Langone Health-Site Number: 8400091, New York
- Columbia University Medical Center-Site Number: 8400138, New York
- и још 2
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Тражи се учесникФаза 3
- Icahn School of Medicine at Mount Sinai /ID# 254880, New York
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Тражи се учесникФаза 3
- New York Presbyterian Hospital, New York
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Тражи се учесникФаза 3
- Icahn School of Medicine at Mount Sinai, New York
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Тражи се учесникФаза 3
- Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC), New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center/New York Presbyterian, New York
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Тражи се учесникФаза 2
- Northwell Health-Lenox Hill Hospital /ID# 265527, New York
Standardized Microbiota Transplant Therapy in Crohn's Disease
Тражи се учесникФаза 2
- NYU Langone Health, New York
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
Тражи се учесникФаза 3
- Weill Cornell Medicine, New York
Behavioral Therapy for Crohn's Disease
Тражи се учесник
- Icahn School of Medicine at Mount Sinai, New York
- New York Gastroenterology Associates, New York
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Тражи се учесник
- NYU Langone Health, New York
- Cornell University, New York
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
Тражи се учесникОпсервациона студија
- New York University, New York
Low Dose IL-2 for the Treatment of Crohn's Disease
Тражи се учесникФаза 1/2
- Mount Sinai, New York
Autologous Stem Cell Transplant for Crohn's Disease
Тражи се учесникФаза 2
- Icahn School of Medicine at Mount Sinai, New York
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
Тражи се учесникФаза 2
- Icahn School of Medicine at Mount Sinai, New York
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Тражи се учесникФаза 3
- Columbia University Medical Center, New York-Presbyterian Hospital, New York
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
Тражи се учесник
- Weill Cornell Medical College, New York
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Тражи се учесникФаза 2
- Mirador Therapeutics Selected Site, New York
Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
- Icahn School of Medicine at Mount Sinai, New York
Treatment of Moderate to Severe Refractory Crohn's Disease
Тражи се учесникФаза 1/2
- Mount Sinai Health Systems, New York
Helmsley 3.0: Abbreviated MRE
Тражи се учесникОпсервациона студија
- NYU Langone, New York
Studije za Кронова болест u drugim gradovima
- St. Louis, MO19 студија
- Miami, FL19 студија
- Orlando, FL19 студија
- Boston, MA18 студија
- Houston, TX17 студија
- Atlanta, GA16 студија
- Tyler, TX16 студија
- San Diego, CA15 студија
- Cleveland, OH15 студија
- Colorado Springs, CO14 студија
- San Antonio, TX14 студија
- Los Angeles, CA13 студија
Ostale studije u gradu New York City
- Рак дојке144 студија
- Немалоклетни карцином плућа123 студија
- Рак (све врсте)105 студија
- Рак простате101 студија
- Метастатски карцином93 студија
- Колоректални карцином86 студија
- Рак јајника75 студија
- Рак плућа60 студија
- Многи мијелом59 студија
- Рак панкреаса57 студија
- Карцином ендометријума54 студија
- Akutna mijeloidna leukemija51 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.